文献速递类风湿关节炎

背景糖皮质激素使用对类风湿关节炎试验中托珠单抗、阿达木单抗或甲氨蝶呤单药治疗疗效与安全性结局的影响

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
PubMed 文献 · Ann Rheum Dis · 2020-02-07

该研究分析四项双盲随机对照试验(AMBITION、ACT-RAY、ADACTA、FUNCTION)共四个托珠单抗、一个阿达木单抗和两个甲氨蝶呤单药治疗臂的数据,比较背景糖皮质激素使用与否对24周疗效指标及104周影像学进展的影响。结果显示除一个甲氨蝶呤臂中糖皮质激素使用与较少影像学进展相关外,疗效参数和严重不良事件发生率在糖皮质激素使用者与非使用者间均无统计学显著差异。

要点

  • 背景糖皮质激素使用未显著影响托珠单抗、阿达木单抗或甲氨蝶呤单药治疗试验的疗效结局。
  • 仅一个甲氨蝶呤臂中糖皮质激素使用与较少影像学进展相关。
  • 糖皮质激素使用者与非使用者的严重不良事件发生率无统计学显著差异。

核心结论

  • 纳入背景糖皮质激素治疗的患者对类风湿关节炎随机对照试验的疗效和安全性结局无影响,但一个甲氨蝶呤臂中糖皮质激素使用与影像学关节损伤减少相关。

研究设计与样本

  • 分析四项双盲类风湿关节炎随机对照试验(AMBITION、ACT-RAY、ADACTA和FUNCTION)的数据,共四个托珠单抗、一个阿达木单抗和两个甲氨蝶呤单药治疗臂。

主要发现

  • 背景糖皮质激素使用者与非使用者之间疗效参数无统计学显著差异, except 一个甲氨蝶呤臂中糖皮质激素使用与较少影像学进展相关。
  • 各治疗臂中糖皮质激素使用者与非使用者的严重不良事件发生率无统计学显著差异。

关键数值与推荐

  • 疗效终点分析为从基线至第24周的变化,影像学进展评估至第104周,采用协方差分析校正相关协变量。

临床怎么用

  • 在解读类风湿关节炎随机对照试验结果时,背景糖皮质激素使用可能不影响疗效和安全性结论,但需注意个别甲氨蝶呤臂中影像学进展的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes. OBJECTIVES: To determine if inclusion of patients on background GC use influenced efficacy and safety outcomes of RA randomised clinical trials on initiation of tocilizumab (TCZ) or adalimumab (ADA) or methotrexate (MTX) monotherapy. METHODS: Data of four double-blind RA randomised controlled trials (AMBITION, ACT-RAY, ADACTA and FUNCTION) with in total four TCZ, one ADA and two MTX monotherapy arms were analysed. Analyses of covariance of changes from baseline to week 24 in efficacy endpoints and radiographic progression up to week 104 were performed, correcting for relevant covariates. Incidence rates of serious adverse events (SAEs) were assessed. RESULTS: No statistically significant differences were found in efficacy parameters between background GC users and non-GC users, except for less radiographic progression associated with GC usage in one MTX arm. SAE rates were not statistically significantly different between GC users and non-GC users in the treatment arms. CONCLUSION: No effect of including patients on background GC treatment on efficacy and safety trial outcomes was found, with the exception of reduced radiological joint damage in one MTX arm.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Safy-Khan M, Jacobs JWG, de Hair MJH, et al. Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy. Ann Rheum Dis. 2020. PMID: 32033935. doi:10.1136/annrheumdis-2019-216537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。